Y’All: I still don’t really know what the BIS Science and Society strategy is about, do you?

I've been meaning to post this ever since it came across my Twitter feed some weeks ago. If you go on the Department for Business, Innovation and Skills (BIS) Science and Society Strategy pages you'll see that they have published updated action plans for each of the 'Expert Groups' set up in 2010.  These groups were tasked to... Continue Reading →

There is no point to the javelin

It has come to this.  The world's top tennis players rush their shots to beat an 11pm curfew.  Bruce and Sir Paul are turned-off mid-performance.  And they don't use real javelins in schools. Looking across the the athletics field at my sons' school sports day, I spied a clutch of children competing in the javelin.  Except this... Continue Reading →

Regulators push openness agenda on raw trial data…and EUPATI issues call for examples of educational materials on medicines development

Yes, that is a long headline is it not?  PharmaTimes and others cover a paper in PloS Medicine authored by a number of medicines regulators including the European Medicines Agency (EMA), calling for openness in raw trial data. The three pronged approach they suggest looks like a good basis for discussion.  It would be interesting... Continue Reading →

EU initiative to boost information for patients on medicines development

The EU economy might be splintering apart.  But, meanwhile, a number of patient/public/private organisations are 'euro-zoning' in on the task of providing better information for patients on medicines development. The new initiative - which was launched on 1st February - is called the European Patients Academy on Therapeutic Innovation  or EUPATI for short. Thank goodness they did... Continue Reading →

Ill-informed consent: EU meeting lays into clinical trials small print for patients

Image by erjkprunczyk via FlickrDaniel Cressey at Nature has written this report from last week's meeting of the European Forum for Good Clinical Practice which took place in Brussels. The basic thrust of the discussion at the meeting was that information given to patients prior to them signing up for a clinical trial: is often vague, too long,... Continue Reading →

Blog at WordPress.com.

Up ↑

%d bloggers like this: